Member Info for sharehunter3

now thinking of buying more ncyt ,already a high percentage of my investment moved into ncyt ,
thinking next week and up to 17th October ,might see more rns being released

if news is released then might be difficult for mms and some buying in.
was seen yesterday how difficult to buy at times ,with out being quoted NT to buy when it looked as if mms were low with available shares ,

will there be news before AGM
will be interesting to see

https://www.wallstreet-online.de/nachricht/12939094-novacyt-s-a...
1 day ago · The Novacyt Group is an international diagnostics business generating an increasing portfolio

MARKET REPORT: Novacyt sales up tenfold amid battle to ...
https://www.thisismoney.co.uk/money/markets/article-8744761
12 hours ago · MARKET REPORT: French Covid test maker Novacyt sales up tenfold since start of year amid battle to beat virus. By Francesca Washtell For The Daily Mail. Published: 16:54 EDT, 17

reposted this ,for previous post ,after looking at 5 year estimate ,if achieves ,any where near estimate price of £21 will be very pleased
https://walletinvestor.com/lse-stock-forecast/ncyt-stock-prediction#open

my plan is to hold some of these for 5 years ,when i look at estimate for 5 year investment if any where near estimate
will be happy with my investment ,if achieves £21 would be be very pleased
,how much news will ncyt ,release in next week before AGM .
also how much news before end of bonus month 17th October
with so much news due ,thinking plenty of rns to be seen

if enough sellers cleared at this level ,and being replaced by buyers as seen some chunky buys this morning ,if a rns before end of trading ,or next week ,before AGM then share price more likely to rocket ,good to see sellers out and replaced at each level ,before next rns

https://walletinvestor.com/lse-stock-forecast/ncyt-stock-prediction#open

The current COVID-19 pandemic has enabled Novacyt to demonstrate its unique ability to design and develop world-class clinical diagnostic products. Being one of the first to market with its PCR COVID-19 test has transformed the business from a very low market cap to a small cap with the potential to become an exciting mid-cap business. We also believe there is significant longevity in the demand for COVID-19 testing and this will mean Novacyt can continue to grow and drive significant cash flow.

This value creation will be used to deliver new growth in the rapidly expanding clinical diagnostics market. The pandemic has brought a global spotlight on the importance of diagnostic testing and we also believe this focus and interest will drive myriad new opportunities in the Diagnostics market. Novacyt is front and centre in supporting the world’s healthcare professionals during this challenging time and is in a strong position to build financial resources to maximise this long-term diagnostics opportunity.


Https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/

while i usually like to see morning rns ,instead of the rns ncyt have released ,late afternoon ,or near end of trading ,
if a good rns tomorrow, hoping it another late afternoon rns for people to be able to read over weekend

Https://www.sharebuyers.co.uk/shares/novacyt-shares-going-for-growth-poised-for-mid-cap-stardom/
A key challenge for any manufacturer supporting COVID-19 on a global basis has been the ability to expand and control its manufacturing capacity. We are immensely proud that we have scaled-up our manufacturing capacity by over 100 times in less than six months and can scale-up further as we add new products and as the market increases.

We now have significant levels of stock in order to respond to emergency customer demands and we are able to provide our customers the confidence in supply continuity. With the uncertainties of border controls, disrupted global transportation and uncertainties such as BREXIT we believe supply chain certainty is a key competitive advantage. Novacyt will continue to ensure that maintains its innovative, high performance position as the pandemic continues.

EBITDA

The Group continued its profitability trend delivering an EBITDA of €49.4m in the first half of 2020. The underlying Primerdesign EBITDA margin has increased to over 80% from 40% in H1 2019 when management charges are excluded, demonstrating that the division can be scaled without significant additional overheads. With Primerdesign delivering approximately 98% of Group revenue in H1 2020 at 85% gross margin, its continued success contributes substantially to the Group's positive EBITDA as the effect of increasing Primerdesign revenues as a percentage of overall Group revenues has been to enhance the overall profitability of the Group.



To support the substantial growth seen by the Group in 2020, investment has been made in overheads including the hiring of new staff and additional facilities spend to maximise manufacturing output. As a percentage of revenue these incremnental costs are negligible, which is reflected in the Group delivering an EBITDA margin of 68% in H1 2020.

Centralised and decentralised testing markets

COVID-19 continues to present Novacyt with a significant opportunity to place rapid mobile instruments where the shortage of testing capacity and limitations of laboratory-based testing is driving healthcare away from large centralised platforms into decentralised more flexible platforms. Beyond COVID-19, Novacyt believes there is the potential for a long-term shift in testing policy towards decentralisation. With the launch of Novacyt's near-patient testing system in July 2020, the Company is well positioned to address this drive towards rapid, decentralised testing.



The pandemic has also highlighted the limitations of closed testing systems (platforms which are only compatible with tests supplied by the instrument manufacturerer) in centralised laboratories where availability of tests and related consumables has been limited and has, therefore, impacted utilisation of testing capacity. The Company believes healthcare providers will identify a need to have more open systems (platforms which are compatible with tests from a variety of suppliers) along with a decentralised testing policy. Both shifts in policy would play to core strengths of Novacyt.

LOOKING at number of recommends for 11,53 post of HillSeeker ,good to see a good post receiving so many recommendations

CHUNKIER BUYS coming in again

buys starting to build

France now back up to 411 euro ,

last 15 minutes ,likely to see nice buying ,for people who wanting in before more rns are released

if another good rns in morning ,hoping for another good move up with share price ,even better if a rns before close tomorrow for people to read it over weekend